Top

International Journal of Colorectal Disease

Published in:

01-07-2012 | Original Article

Ezrin expression in rectal cancer predicts time to development of local recurrence

Authors: Fredrik Jörgren, Mef Nilbert, Eva Rambech, Pär-Ola Bendahl, Gudrun Lindmark

Published in: International Journal of Colorectal Disease | Issue 7/2012

Abstract

Purpose

Improved outcome after rectal cancer surgery requires identification of novel risk factors of tumour recurrence in order to personalise therapy, that is, enhanced selection of high-risk patients to additional radiochemotherapy or intensified follow-up. In several tumour types, including colorectal cancer, high expression of the membrane–cytoskeleton linker ezrin has been suggested to impair prognosis but has not yet reached clinical application. We evaluated the expression of ezrin in rectal cancer with a focus on the identification of a marker for local tumour recurrence.

Methods

Immunohistochemical expression of ezrin was analysed in 104 primary rectal cancers from patients who developed local recurrences despite being treated with R0 major abdominal surgery. Time to local recurrence and distant metastasis as well as 5-year overall and cancer-specific survival were used as end points.

Results

Ezrin expression was weak in 17% of the tumours, moderate in 62%, and intense in 21%. The time to local recurrence was significantly shorter (p = 0.0004) for patients with tumours showing high ezrin expression. No correlation between ezrin expression and time to distant metastasis was identified. Survival data were similar between groups irrespective of ezrin expression in the primary tumours.

Conclusions

Our findings suggest that increased expression of ezrin may represent a marker of aggressive biological behaviour in rectal cancer. Although further validation is needed, ezrin may represent a relevant marker for personalised treatment of rectal cancer with respect to risk of local recurrence after R0 surgery.

Wibe A, Carlsen E, Dahl O, Tveit KM, Weedon-Fekjaer H, Hestvik UE, Wiig JN; Norwegian Rectal Cancer Group (2006) Nationwide quality assurance of rectal cancer treatment. Colorectal Dis 8:224–229CrossRef

Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, van de Velde CJ, Dutch Colorectal Cancer Group (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701PubMedCrossRef

Pahlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödahl R, Öjerskog B, Damber L, Johansson R (2007) The Swedish Rectal Cancer Registry. Br J Surg 94:1285–1292PubMedCrossRef

Jörgren F, Johansson R, Damber L, Lindmark G (2010) Risk factors of rectal cancer local recurrence: population-based survey and validation of the Swedish Rectal Cancer Registry. Colorectal Dis 12:977–986PubMedCrossRef

Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138:2073–2087PubMedCrossRef

Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ (2004) The membrane–cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10:182–186PubMedCrossRef

Tynninen O, Carpén O, Jääskeläinen J, Paavonen T, Paetau A (2004) Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol 30:472–477PubMedCrossRef

Weng WH, Ahlén J, Aström K, Lui WO, Larsson C (2005) Prognostic impact of immunohisto-chemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 11:6198–6204PubMedCrossRef

Köbel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, Wolters M, Dittmer J, Strauss HG, Thomssen C, Hauptmann S (2006) Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 25:121–130PubMedCrossRef

10.

Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM, Khanna C (2007) Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 24:69–78PubMedCrossRef

11.

Brambilla D, Fais S (2009) The Janus-faced role of ezrin in “linking” cells to either normal or metastatic phenotype. Int J Cancer 125:2239–2245PubMedCrossRef

12.

Xie JJ, Xu LY, Xie YM, Zhang HH, Cai WJ, Zhou F, Shen ZY, Li EM (2009) Roles of ezrin in the growth and invasiveness of esophageal squamous carcinoma cells. Int J Cancer 124:2549–2558PubMedCrossRef

13.

Cui Y, Li T, Zhang D, Han J (2010) Expression of Ezrin and phosphorylated ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest 28:242–247PubMedCrossRef

14.

Vaheri A, Carpén O, Heiska L, Helander TS, Jääskeläinen J, Majander-Nordenswan P, Sainio M, Timonen T, Turunen O (1997) The ezrin protein family: membrane–cytoskeleton interactions and disease associations. Curr Opin Cell Biol 9:659–666PubMedCrossRef

15.

Hiscox S, Jiang WG (1999) Ezrin regulates cell–cell and cell–matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci 112:3081–3090PubMed

16.

Hunter KW (2004) Ezrin, a key component in tumor metastasis. Trends Mol Med 10:201–204PubMedCrossRef

17.

Fehon RG, McClatchey AI, Bretscher A (2010) Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 11:276–287PubMedCrossRef

18.

Yan G, Zhou X, Xiao X, Lu H, Du X (2007) Ezrin expression and its translocation in human primary sporadic colorectal carcinoma and prognostic significance. Chinese-German J Clin Oncol 6:232–236CrossRef

19.

Nowak D, Mazur AJ, Popow-Woźniak A, Radwańska A, Mannherz HG, Malicka-Błaszkiewicz M (2010) Subcellular distribution and expression of cofilin and ezrin in human colon adenocarcinoma cell lines with different metastatic potential. Eur J Histochem 54:59–66CrossRef

20.

Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze’ev A (2010) Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci 123:2135–2143PubMedCrossRef

21.

Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkilä S, Vaheri A, Syrjänen K, Pyrhönen S, Carpén O (2008) Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol 39:1737–1743PubMedCrossRef

22.

Wang HJ, Zhu JS, Zhang Q, Sun Q, Guo H (2009) High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy. World J Gastroenterol 15:2016–2019PubMedCrossRef

23.

Korkeila EA, Syrjänen K, Bendardaf R, Laulajainen M, Carpén O, Pyrhönen S, Sundström J (2011) Preoperative radiotherapy modulates ezrin expression and its value as a predictive marker in patients with rectal cancer. Hum Pathol 42:384–392PubMedCrossRef

24.

Jung EJ, Lee JH, Min BW, Kim YS, Choi JS (2011) Clinicopathologic significance of fascin, extracellular matrix metalloproteinase inducer, and ezrin expressions in colorectal adeno-carcinoma. Indian J Pathol Microbiol 54:32–36PubMedCrossRef

25.

He ZY, Wen H, Shi CB, Wang J (2010) Up-regulation of hnRNP A1, Ezrin, tubulin β-2 C and Annexin A1 in sentinel lymph nodes of colorectal cancer. World J Gastroenterol 16:4670–4676PubMedCrossRef

26.

Holm T, Cedermark B, Rutqvist LE (1994) Local recurrence of rectal adenocarcinoma after ‘curative’ surgery with and without preoperative radiotherapy. Br J Surg 81:452–455PubMedCrossRef

27.

Merkel S, Mansmann U, Hohenberger W, Hermanek P (2011) Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment. A systematic review and meta-analysis. Colorectal Dis 13:123–131PubMedCrossRef

28.

Yao Y, Jia XY, Tian HY, Jiang YX, Xu GJ, Qian QJ, Zhao FK (2009) Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta 1794:1433–1440PubMed

29.

Rebillard A, Jouan-Lanhouet S, Jouan E, Legembre P, Pizon M, Sergent O, Gilot D, Tekpli X, Lagadic-Gossmann D, Dimanche-Boitrel MT (2010) Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer 46:1445–1455PubMedCrossRef

30.

Blomqvist L, Glimelius B (2008) The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers. Acta Oncol 47:5–8PubMedCrossRef

Title: Ezrin expression in rectal cancer predicts time to development of local recurrence
Authors: Fredrik Jörgren
Mef Nilbert
Eva Rambech
Pär-Ola Bendahl
Gudrun Lindmark
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 7/2012
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-011-1397-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ezrin expression in rectal cancer predicts time to development of local recurrence

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2012

High-intensity focused ultrasound as a treatment for colorectal liver metastasis in difficult position

The clinical impact of preoperative percutaneous drainage of abdominopelvic abscesses in patients with Crohn’s disease

Sacral nerve modulation in the treatment of chronic pelvic pain

The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study

Hepatoid adenocarcinoma of the transverse colon

GSTM1 and GSTT1 polymorphisms and colorectal cancer risk in Chinese population: a meta-analysis